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Objectives: Hepatitis C Virus (HCV) infection is a significant public health issue 
in China. In 2006, a national seroepidemiological survey of HCV showed 5.6 million 
people were tested with HCV positive. Although new cases with HCV infection 
are mandatory to report in China, it is believed that the reported information is 
under-reported. The objective of this study was to correctively estimate newly 
infected HCV cases by gender, age, and province in China from 2005 to 
2013. MethOds: The Back-calculation method was used to estimate the initial 
number of HCV infection, based on annual HCV reported cases issued by China 
CDC and the incubation distribution of HCV, which was from an outbreak due to 
a medical accident at a county in Liaoning, China in 2012; then the Expectation 
Maximization (EM) algorithm was employed to obtain the optimization estima-
tion of HCV infection. Prior to the estimation, a rate of 49.7% from Denniston’s 
study, in which subjects were not aware that they were infected with HCV was 
considered in the calculation to control for the missing report. The Monte Carlo 
simulation was applied to calculate total numbers and their 95% CIs. Results: 
The estimated numbers of newly-infected HCV cases from 2005 to 2013 were 
nearly 3.4 million. While 57.8% of the estimated newly-infected cases were 
male, cases of 30 to 39 years old were the group with the highest newly-infected 
cases of HCV (n= 963, 304, 28.4%). The estimated newly-infected cases also showed 
geographic variations that north, southwest, and west were among the regions 
where higher numbers were found. cOnclusiOns: This is the first time to 
correctively estimate newly-infected HCV cases using the annual infection dis-
ease report of China CDC; however, this estimation may still be underestimated 
because of the low unawareness of HCV and high rate of missing report on HCV 
cases in China.
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Objectives: - This paper focuses on this knowledge gaps for informed decision-
making and identifies key barriers in uptake PCV in India. MethOds: - Qualitative 
interviews were conducted with pediatricians registered with Indian Academy of 
Pediatrics to generate evidence on perspective and practices regarding the PCV. 
A multi-level stratified sampling was applied to identify pediatricians across 12 
metropolitan cities. The analysis was conducted using standard qualitative tech-
niques to identify key domains, words, phrases and concepts from respondents. 
Quantitative variables are reported as mean and proportions. Results: -Majority 
(67.7%) of pediatricians advice for PCV to all whereas 32.2% advice PCV only to 
those who can afford. Around half (50.8%) have no specific preference and rec-
ommend any PCV vaccine where as 28.0% recommend PCV13. Main reason for 
acceptance of PCV were educated and informed clients (50.8%) followed by pedia-
trician’s advice and counseling (25.4%) whereas main reason for denial was price 
of vaccine (97.3). In addition, majority (74.1%) of pediatricians wanted PCV to be 
included into UIP whereas (17.7%) didn’t and (8.0%) were not sure. cOnclusiOns: 
- Pediatricians should put efforts to increase awareness about vaccine prevent-
able disease among their clients and can facilitate bridge the knowledge action 
gap by helping their clients to make informed decision with regards to uptake of 
newer vaccines.
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Objectives: Acinetobacter genuses of bacteria have become a challenge for every 
hospital with regards to its treatment and cost of therapy due to its penchant to 
acquire resistance. The aim of the present study was to ascertain the prescribing 
pattern of antibiotics in Acinetobacter infection. MethOds: A cross sectional, 
observational, retrospective study was carried out, over a period of 6 months in 
a tertiary care hospital. The data collected was analysed to understand the pat-
tern with respect to patient demographics, prescription patterns, co-morbidities 
as risk factors to infection, and resistance patterns. Results: The study results 
showed that male patients had greater risk for A. baumannii infections with an 
age group of 41-60 years. The length of stay of a patient of A. baumanni infec-
tion was 23.51±27.97 days. The bacteria were found to be resistant to almost 
all categories of drugs. Based on the study of prescription of antibiotics it was 
found that empirical antibiotic therapy was prescribed to most patients. with the 
most prescribed drug being tigecycline and cefixime in 47 (97.9%) patients. The 
least prescribed antibiotic was Piperacillin – Tazobactam prescribed to 25 (42.9%) 
patients. Cefoperazone-sulbactam was found to have an antibiotic action against 
the bacterium. cOnclusiOns: The study concluded that male patients were at 
a greater risk of A. baumannii infections. Length of stay of patients was on aver-
age 23.51±27.97 days. The study showed tigecycline and cefixime were the most 
prominently used antibiotic. The strain in this study was resistant to almost all 
cephalosporins except Cefoperazone-Sulbactam which had activity in 57.14% of 
the samples tested.
Objectives: To evaluate the effectiveness of an antimicrobial stewardship pro-
grams. MethOds: The antimicrobial stewardship program was started since 
November 1, 2012, and pharmacists would intervene when antimicrobial agents, 
including levofloxacin, teicoplanin, meropenem, tigecycline and piperacillin/tazo-
bactam, were used for more than 7 days. Inpatients who previously received any 
one of the 5 agents from 2011/11/1 to 2012/10/31 (phase 1) and from 2012/11/1 to 
2013/10/31 (phase 2) were included. Patients’ personal data, indication, residency, 
surgery history, duration of therapy, duration of hospital stay, quantity of antibi-
otics use and the cost of antibiotics were collected. The primary outcome was to 
compare the amount of antibiotics usage in defined daily doses (DDD per 1000 
patient-days) between the 2 phases. Secondary outcomes were to compare the 
duration of therapy, the proportion of patients having prolonged antibiotic use over 
14 days, the duration of hospital stay, expense of antibiotics, and readmission rate 
in 30 days. Results: A total of 8,781 patients were included. 4,571 patients were 
in phase 1 and 4,210 were in phase 2. The most prevalent indications for antibiotic 
use were pneumonia and urine tract infection. The total quantity of antibiotics in 
phase 2 was significantly decreased from 224.08 DDD to 188.89 DDD as comparing 
with phase 1. The DDDs of each agent in phase 2 were also significantly decreased 
respectively. After the program implementation, the expense of antibiotics, duration 
of therapy, proportion of patients having prolonged antibiotic use over 14 days and 
duration of hospital stay were all significantly decreased. The readmission rate in 
30 days did not differ between the two phases. cOnclusiOns: The implementa-
tion of antimicrobial stewardship program was effective in reducing the amounts 
of antibiotics usage, and it may reduce the inappropriate use of antibiotics, shorten 
the duration of therapy and save medical expense without affecting quality of care 
in term of readmission rate.
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Objectives: According to the World Health Organisation, the emergence of resist-
ant organisms has rendered antibiotics ineffective in some settings (1). In an 
attempt to address current and future unmet needs in this area innovative anti-
biotics are being developed. We conducted a review of recent HTA evaluations for 
antibiotics to investigate whether policy initiatives to promote advances in antibiot-
ics are reflected in reimbursement decisions. MethOds: The guidance directories 
of the Scottish Medicines Consortium (SMC), All Wales Medicines Strategy Group 
(AWMSG) and the National Institute for Health and Care Excellence (NICE) were 
reviewed for assessments of antibiotics, from 2000 until May 2014. Data relating to 
each assessment were extracted. A simple scoring system for the reimbursement 
decisions by the SMC and AWMSG was adopted: where a “positive” reimburse-
ment decision scored 3, “Restricted use” scored 1, “Not yet reviewed” scored 0 and 
“Rejected” scored -1. Results were plotted to show the positioning of reimbursement 
decisions of AWMSG in relation to SMC. Results: A total of 18 antibiotics were 
identified as having been assessed by either SMC or AWMSG. Of these 18 products, 
only 2 were assessed by NICE, and a further 2 were the subjects of “Evidence Review 
Summaries”, product overviews that are not legally binding. Of the 18 antibiotics 
identified, only 3 and 2 received “Positive” reimbursement decisions by the SMC 
and AWMSG, respectively. Four antibiotics were “Not Recommended” by both SMC 
and AWMSG, of which several rejections were due to pharmaceutical companies 
not submitting dossiers to the regulatory body. Scatterplots of SMC and AWMSG 
scores featured six antibiotics in the top right quadrant. cOnclusiOns: This study 
demonstrates the different assessment approaches by each regulatory body for 
antibiotics. Moreover, the low number of antibiotics reviewed highlights that the 
dearth of new, innovative antibiotics are not in keeping with policies to develop 
innovative antibiotics.
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Objectives: Analyzing population distribution, temporal and spatial clustering, 
and changing trend of Hepatitis C Virus（HCV（ in order to provide the evidence-based 
decision making for the control and prevention of HCV. MethOds: HCV cases were 
extracted from the National Diseases Reporting System of China CDC between 2008 
and 2013. Spatial scanning unit was 2886 districts/counties in mainland China; 
temporal scanning unit was month, and time span was from Jan 2008 to Dec 2013. 
Kulldorff scan statistic was applied, and analyses were conducted by SaTScanTM 9.1. 
Making maps and visualizing results were carried out with ArcGIS 10.1. Results: 
Monitoring data of HCV from 2008 to 2013 demonstrated that most cases of HCV 
occurred between 30 to 59 years old, above 60%; males were more than females, 
the ratio of males to females was 1.20-1.35; the percentage of peasants was nearly 
60%. Results from SaTScan illustrated that the temporal and spatial clustering was 
existed for HCV; temporal dimension of HCV occurrence was from June to October 
of each year; spatial dimension was located in north-east area and north-west area. 
With respect to the changes of temporal and spatial clustering, class 1 clustering 
area was always located in the Middle of China. In 2011, it expended to the west 
half of China. Class 2 clustering area was stable and located in north-west of China, 
except for 2012. Class 3 clustering area was located in north-east of China, but it 
became smaller in 2013. Class 4 and 5 clustering area was located in south of China, 
and it became larger with time. cOnclusiOns: Temporal and spatial clustering 
area of HCV was presented in this report, and its own changing pattern of clustering 
areas with years was noted. Findings from this paper will provide evidence-based 
decision making to prevent HCV infection, guide stockages and allocations of health 
resources, and to formulate HCV prevention and control strategies.
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als in 14 countries to access unpublished information and assess the acceptability 
of different MEA types across Europe. Outputs were developed into a vaccines 
specific MEA framework and guidance for implementation. Results: To date, 
there is very little experience with vaccine MEAs in Europe; however, interest-
ing value-added service examples were identified (e. g. educational campaign 
support). The vaccine-specific MEA framework developed (aligned with cur-
rent taxonomy) focused on financial schemes (e. g. staggered entry approaches, 
volume-based discounts, price-volume agreements), coverage with evidence 
development and value-added services (e. g. vaccination implementation sup-
port). Pay-for-performance MEAs were less applicable. Budget holder feedback 
in selected countries confirmed their interest in co-creating such MEA/service 
approaches with vaccine companies. cOnclusiOns: To enable decision makers 
to continue investing in innovative vaccines that address public health needs, a 
shift towards new value-based acquisition models is key. A broader, more flexible 
approach to vaccines access, including MEAs, can address the needs of budget 
holders and other external stakeholders as well as manufacturers.
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Objectives: Vaccines face increasing reimbursement and access challenges in 
many European markets. Decision makers are facing uncertainties in terms of 
budget impact planning, vaccines’ expected impact and vaccination implementa-
tion. This has led to major delay in the population access to vaccination, and to 
commoditization of some vaccinations. However, innovation in vaccines access 
has been more limited than for pharmaceuticals, where there is a longer history 
of adapting to pricing and access pressure. Building on the experience of managed 
entry agreements (MEAs) used for drugs, the project aimed to develop a framework 
of MEAs and value-added services specifically applicable to vaccines. MethOds: 
Literature and web searches were performed to document MEA taxonomy and 
identify real world European MEA examples for pharmaceuticals and vaccines. 
This was followed by an on-line/telephone survey with SPMSD access profession-
